Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences (Nasdaq: PCRX) reported Q1 2026 results: $177.4M total revenue (+5% vs. Q1 2025), GAAP net income of $2.9M ($0.07/share), and non-GAAP net income of $24.5M ($0.60/share). Adjusted EBITDA was $40.2M. The company completed enrollment in a Phase 3 ZILRETTA shoulder OA study and repurchased 2.2M shares for $50.0M. Pacira reiterated full-year 2026 guidance, including EXPAREL sales $600M–$620M and total revenue $745M–$770M.
Pacira BioSciences (NASDAQ: PCRX) filed definitive proxy materials for its June 9, 2026 Annual Meeting and mailed a shareholder letter urging a vote “FOR” the company’s three nominees on the BLUE proxy card. The company highlights its 5x30 strategy, >35% stock gain since launch, 2025 operational milestones, patent estate expansion, $200M+ share repurchases, and upcoming 2026 clinical and registrational readouts.
Pacira BioSciences (NASDAQ: PCRX) presented a retrospective Medicare real‑world study showing EXPAREL (bupivacaine liposome) was associated with lower opioid consumption, reduced healthcare utilization, and lower total medical costs versus non‑liposome bupivacaine after outpatient total hip arthroplasty over 12 months.
Key results: reduced MMEs at 30/90/180/365 days, fewer inpatient admissions and outpatient visits, and lower total medical costs at 30/90/180/365 days.
Pacira (Nasdaq: PCRX) will report first quarter 2026 financial results after market close on Thursday, April 30, 2026.
Following the release, Pacira will host a live conference call and webcast at 4:30 p.m. ET; telephone participants must pre-register to receive dial-in information and a PIN. A webcast replay will be available on the company website for about two weeks.
Pacira (NASDAQ: PCRX) presented three real-world HOPD analyses at AMCP 2026 showing EXPAREL (liposomal bupivacaine) was associated with lower or comparable total healthcare costs and reduced opioid use in select cohorts through six months.
Key findings: THA costs were lower at 3 months ($7,332 vs $8,153) and 6 months ($13,022 vs $15,081); TKA showed comparable or lower costs, notably in teaching hospitals; a 3-year budget model projected −$117,868 per 1M members versus ropivacaine.
Pacira BioSciences (Nasdaq: PCRX) will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on April 15, 2026. Live audio and a replay (available for two weeks) can be accessed via the company events page.
Pacira also granted inducement equity awards on April 2, 2026: stock options aggregating 5,000 shares (10-year term, exercise price $22.70, four-year vesting) and restricted stock units aggregating 13,000 shares (four annual vesting installments beginning April 1, 2027). Awards were approved by the People & Compensation Committee under Nasdaq Rule 5635(c)(4).
Pacira BioSciences (NASDAQ: PCRX) presented two propensity score–matched real-world studies at ORS 2026 showing EXPAREL (liposomal bupivacaine) was associated with lower total cost of care versus ropivacaine and versus non-LB analgesia in TKA and spinal fusion. Reported benefits included lower 30-day total costs, reduced select resource use, and a shorter hospital length of stay in spinal fusion.
Summary not available.
Pacira BioSciences (Nasdaq: PCRX) responded to DOMA's nomination of three director candidates and reaffirmed its 5x30 strategy to drive long-term shareholder value. Key 2025 results: 2.5 million patients treated, EXPAREL volume +6.2% YoY, GAAP gross margin 79% (non-GAAP 81%), and $150 million share repurchases reducing shares from 47 to 41 million. The company highlighted expansion of its EXPAREL patent estate to 21 Orange-Book listed patents, progress in Phase 2 programs PCRX-201 and PCRX-2002, and several 2026 clinical milestones including a Phase 3 interim analysis and multiple topline readouts.
Summary not available.